[go: up one dir, main page]

MX2016012620A - Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a). - Google Patents

Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).

Info

Publication number
MX2016012620A
MX2016012620A MX2016012620A MX2016012620A MX2016012620A MX 2016012620 A MX2016012620 A MX 2016012620A MX 2016012620 A MX2016012620 A MX 2016012620A MX 2016012620 A MX2016012620 A MX 2016012620A MX 2016012620 A MX2016012620 A MX 2016012620A
Authority
MX
Mexico
Prior art keywords
antibody
antibodies against
hpa
against hpa
fnait
Prior art date
Application number
MX2016012620A
Other languages
English (en)
Other versions
MX376061B (es
Inventor
Michaelsen Terje
Brynjar Stuge Tor
Husebekk Anne
TILLER Heidi
Eksteen Mariana
Ragnar SKOGEN Bjørn
Ihle Øistein
Original Assignee
Univ I Tromsø - Norges Arktiske Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1405775.6A external-priority patent/GB201405775D0/en
Priority claimed from GBGB1417614.3A external-priority patent/GB201417614D0/en
Application filed by Univ I Tromsø - Norges Arktiske Univ filed Critical Univ I Tromsø - Norges Arktiske Univ
Publication of MX2016012620A publication Critical patent/MX2016012620A/es
Publication of MX376061B publication Critical patent/MX376061B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un anticuerpo aislado que se une específicamente a HPA-1a. También se proporciona una molécula de ácido nucleico que codifica el anticuerpo y composiciones que comprenden el anticuerpo. También se proporciona un método para producir el anticuerpo y métodos y usos que emplean el anticuerpo. También se proporcionan usos terapéuticos del anticuerpo, por ejemplo en el tratamiento o profilaxis de la trombocitopenia aloinmune fetal y neonatal (FNAIT).
MX2016012620A 2014-03-31 2015-03-31 Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a). MX376061B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1405775.6A GB201405775D0 (en) 2014-03-31 2014-03-31 Antibodies
GBGB1417614.3A GB201417614D0 (en) 2014-10-06 2014-10-06 Antibodies
PCT/EP2015/057102 WO2015150417A1 (en) 2014-03-31 2015-03-31 ANTIBODIES AGAINST HPA-1a

Publications (2)

Publication Number Publication Date
MX2016012620A true MX2016012620A (es) 2017-04-06
MX376061B MX376061B (es) 2025-03-07

Family

ID=52785093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012620A MX376061B (es) 2014-03-31 2015-03-31 Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).

Country Status (21)

Country Link
US (2) US10882919B2 (es)
EP (1) EP3126391B1 (es)
AU (1) AU2015239606C1 (es)
BR (1) BR112016022508A2 (es)
CA (1) CA2943857C (es)
CY (1) CY1122728T1 (es)
DK (1) DK3126391T3 (es)
ES (1) ES2757596T3 (es)
HR (1) HRP20192097T1 (es)
HU (1) HUE047455T2 (es)
IL (1) IL247988B2 (es)
LT (1) LT3126391T (es)
ME (1) ME03655B (es)
MX (1) MX376061B (es)
PL (1) PL3126391T3 (es)
PT (1) PT3126391T (es)
RS (1) RS59704B1 (es)
RU (1) RU2688627C2 (es)
SI (1) SI3126391T1 (es)
SM (1) SMT202000052T1 (es)
WO (1) WO2015150417A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212930A1 (en) * 2021-04-02 2022-10-06 Rallybio Ipa, Llc Method of administering anti-hpa-1a gamma globulin
EP4363444A4 (en) * 2021-07-01 2025-04-02 Rallybio IPA, LLC ADMINISTRATION OF ANTI-HPA-1A ANTIBODIES
WO2023278667A1 (en) * 2021-07-01 2023-01-05 Rallybio Ipa, Llc Method of administering anti-hpa-1a monoclonal antibody
IL312596A (en) * 2021-11-08 2024-07-01 Rallybio Ipa Llc ASSAYS FOR QUANTIFICATION OF ANTI-HPA-1a ANTIBODIES
WO2024148187A1 (en) * 2023-01-04 2024-07-11 Rallybio Ipa, Llc Pharmaceutical composition comprising anti-hpa-1a antibody
WO2025117614A1 (en) * 2023-11-27 2025-06-05 Rallybio Ipa, Llc Extended interval administration of anti-hpa-1a antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
GB9223390D0 (en) 1992-11-07 1992-12-23 Common Services Agency Anti-hpa1 testing
GB9505447D0 (en) * 1995-03-17 1995-05-03 Common Services Agency Competitive binding assay
AU7809698A (en) 1997-06-05 1998-12-21 Johns Hopkins University, The Identification of human heavy chain antibody fragment directed against human platelet alloantigen 1a(hpa-1a)
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030027207A1 (en) 2000-02-29 2003-02-06 Filpula David Ray Anti-platelet binding proteins and polymer conjugates containing the same
JP3312204B2 (ja) 2000-10-17 2002-08-05 学校法人 慶應義塾 血小板減少症の診断用キット
GB0315754D0 (en) 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
EP2298785B1 (en) 2004-02-06 2012-07-25 Canadian Blood Services Simultaneous determination of blood group and platelet antigen genotypes
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
EP2397497A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US20090317413A1 (en) 2005-11-15 2009-12-24 Cambridge Enterprise Limited Detection of human platelet antigen (hpa) antibodies
EP1969011B1 (en) 2006-01-03 2012-05-16 TTO Nord AS Preparation for treatment of neonatal alloimmune thrombocytopenia (nait)
ATE468351T1 (de) 2006-02-07 2010-06-15 Diagnostische Forsch Stiftung Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten
WO2007102383A1 (en) 2006-02-28 2007-09-13 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-epha4 antibodies
EP2006304A1 (en) 2007-06-22 2008-12-24 Stiftung Für Diagnostische Forschung Anti-HPA-5b monoclonal antibody
CN101849003A (zh) 2007-05-25 2010-09-29 日本赤十字社 新型GPIIIa基因
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
EA024722B1 (ru) 2008-12-31 2016-10-31 Бхарат Сирумс Энд Вэксинс Лтд. МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА АНТИ-RhD
CN101892314B (zh) 2010-06-22 2012-04-18 天津市秀鹏生物技术开发有限公司 用于检测人血小板同种抗原基因的引物组及试剂盒
DK2796881T3 (en) 2013-04-26 2018-01-02 Davos Diagnostics Ag Platelet allogeneic antigen type and platelet antibody test.

Also Published As

Publication number Publication date
EP3126391B1 (en) 2019-08-21
US10882919B2 (en) 2021-01-05
ME03655B (me) 2020-07-20
SI3126391T1 (sl) 2020-04-30
AU2015239606C1 (en) 2020-08-27
CA2943857C (en) 2023-07-11
IL247988A0 (en) 2016-11-30
US20210189005A1 (en) 2021-06-24
PT3126391T (pt) 2019-11-27
CA2943857A1 (en) 2015-10-08
HRP20192097T1 (hr) 2020-04-03
US11725063B2 (en) 2023-08-15
RS59704B1 (sr) 2020-01-31
US20170121422A1 (en) 2017-05-04
IL247988B1 (en) 2024-03-01
BR112016022508A2 (pt) 2017-10-10
AU2015239606B2 (en) 2020-06-04
AU2015239606A1 (en) 2016-10-20
WO2015150417A1 (en) 2015-10-08
CY1122728T1 (el) 2021-03-12
RU2016142718A3 (es) 2018-10-18
SMT202000052T1 (it) 2020-03-13
IL247988B2 (en) 2024-07-01
NZ724772A (en) 2023-03-31
EP3126391A1 (en) 2017-02-08
RU2688627C2 (ru) 2019-05-22
LT3126391T (lt) 2020-02-10
PL3126391T3 (pl) 2020-05-18
HUE047455T2 (hu) 2020-04-28
MX376061B (es) 2025-03-07
ES2757596T3 (es) 2020-04-29
RU2016142718A (ru) 2018-05-07
DK3126391T3 (da) 2019-11-25

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CY1123642T1 (el) Αντισωματα enanti-pd-1
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
EA202091540A1 (ru) Антитела к lilrb2
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
UY35399A (es) Conjugados de fármacos con anticuerpos
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
JO3671B1 (ar) تراكيب جسم مضاد لـ dll3 وcd3
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2016006232A (es) Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: RALLYBIO IPA, LLC